PF-08052667

N/A

Report date: 2026/04/10 20:01:49

Base Information

Drug NamePF-08052667
Drug Alias NamePF-08052667SGN-B6N
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-ITGB6Tubulin inhibitors
TargetsIntegrin beta-6Tubulin
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceIsrael +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A